Amendments to the Claims

This listing of claims replaces all prior versions and listings of claims in the application. Any amendments or cancellations to the claims are made without prejudice or disclaimer.

1-44. **(Canceled)**

45. **(Previously Presented)** A substantially pure consecutive and anti-angiogenic polypeptide, comprising the central region of human histidine rich glycoprotein (HRGP) corresponding to SEQ.ID.NO:2.

46. **(Previously Presented)** The polypeptide of claim 45, consisting of the central region of human histidine rich glycoprotein (HRGP) corresponding to SEQ.ID.NO:2.

47. **(Previously Presented)** A substantially pure consecutive and anti-angiogenic polypeptide, consisting of a subfragment of the central region of human HRGP (SEQ.ID.NO:2).

48. **(Previously Presented)** The polypeptide of claim 47, said subfragment corresponding to region 330-364 (SEQ.ID.NO: 1) of mature human HRGP.

49. **(Previously Presented)** The polypeptide of claim 47, said subfragment having an amino acid length of between 3 and 35 amino acids.

50. **(Previously Presented)** The polypeptide of claim 49, having an amino acid length selected from the group consisting of between 3 and 25 amino acids, 3 and 20 amino acids, 3 and 15 amino acids, 3 and 10 amino acids, and 3 and 8 amino acids.

51. **(Previously Presented)** The polypeptide of claim 47, said subfragment corresponding to SEQ.ID.NO: 18.

52. **(Previously Presented)** The polypeptide of claim 47, said subfragment corresponding to SEQ.ID.NO: 17.

53. **(Previously Presented)** The polypeptide of claim 47, said subfragment corresponding to SEQ.ID.NO: 16.

54. **(Previously Presented)** The polypeptide of claim 47, said subfragment corresponding to SEQ.ID.NO:22.

55. **(Previously Presented)** The polypeptide of claim 47, said subfragment corresponding to SEQ.ID.NO:21.

56. **(Previously Presented)** The polypeptide of claim 47, said subfragment corresponding to SEQ.ID.NO:24.

57. **(Previously Presented)** The polypeptide of claim 47, said subfragment corresponding to SEQ.ID.NO:23.

58. **(Previously Presented)** The polypeptide of claim 47, said subfragment corresponding to SEQ.ID.NO:26.

59. **(Previously Presented)** The polypeptide of claim 47, said subfragment corresponding to SEQ.ID.NO:25.

60. **(Previously Presented)** The polypeptide of claim 47, said subfragment corresponding to SEQ.ID.NO:28.

61. **(Previously Presented)** The polypeptide of claim 47, said subfragment corresponding to SEQ.ID.NO:27.

62. **(Previously Presented)** The polypeptide of claim 47, wherein said polypeptide is isolated from human HRGP.

63. **(Previously Presented)** The polypeptide of claim 47, wherein said polypeptide is isolated from proteolytically processed human HRGP purified from plasma.

64. **(Previously Presented)** The polypeptide of claim 47, wherein said polypeptide is recombinantly produced or isolated from recombinantly produced human HRGP.

65. **(Previously Presented)** The polypeptide of claim 47, wherein said polypeptide is synthetically produced.

66. **(Previously Presented)** The polypeptide of claims 47, wherein said polypeptide does not promote angiogenesis or does not bind to thrombospondin.

67. **(Previously Presented)** A pharmaceutical composition comprising an effective amount of the polypeptide of claim 47.

68. **(Previously Presented)** The pharmaceutical composition of claim 67, further comprising a pharmaceutically acceptable carrier.

69. **(Previously Presented)** The pharmaceutical composition of claim 67, further comprising an anti-angiogenic agent.

70. **(Previously Presented)** The pharmaceutical composition of claim 69, wherein said anti-angiogenic agent is selected from the group consisting of angiostatin, thrombostatin, endostatin, interferon-α, interferon-inducible factor 10, and platelet factor 4.

71. **(Previously Presented)** The pharmaceutical composition of claim 67, further comprising an anti-neoplastic agent.

72. **(Previously Presented)** The pharmaceutical composition of claim 71, wherein said antineoplastic agent is selected from the group consisting of taxol, cyclophosphamide, carboplatinum, cisplatinum, cisplatin, gancyclovir, camptothecin, paclitaxel, hydroxyurea, 5-azacytidine, 5-aza-2'-deoxycytidine, and suramin.

73. **(Previously Presented)** The pharmaceutical composition of claim 67, further comprising an anti-inflammatory agent.

74. **(Previously Presented)** The pharmaceutical composition of claim 73, wherein said antiinflammatory agent is selected from the group consisting of prednisone, a cox-2 inhibitor, ibuprofen and aspirin.

75. **(Previously Presented)** The pharmaceutical composition of claim 67, further comprising an effective amount of Zn2+.

76-83. **(Canceled)**